ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
21 announcements with these filters
Q2 income up 11% to ₹821 Cr; EBITDA up 41% to ₹202 Cr at 25% margin. Bliss GVS closed 28 Sep, so only three days are consolidated. Management avoided quantifying Bliss and M&A.
Q2FY27 consolidated total income ₹821 Cr (+11% YoY), EBITDA ₹202 Cr (+41%, 25% margin), PAT ₹65 Cr (+14%). Controlling stake in Bliss GVS Pharma acquired 28 Sep 2026.
Anupam Rasayan India Ltd reported revenue from operations of ₹805.9 Cr (+10.2% YoY) and net profit of ₹65 Cr (+13.6% YoY) for Q2 FY27.
Anupam Rasayan India scheduled a November 6, 2026 board meeting to approve unaudited standalone and consolidated results. The trading window stays closed until November 8.
Anupam Rasayan India Limited filed copy of minutes of its Annual General Meeting held on September 30, 2026. The filing is procedural and carries no financial or business event.
Anupam Rasayan India disclosed a Crisil ESG rating of 62 and Core ESG rating of 63 (Strong). No transaction or business decision is involved.
Catalyst Trusteeship Ltd, as Debenture Trustee, received pledge on 24,62,215 shares of Anupam Rasayan India. Encumbered stake rose from 14.90% to 17.07% of total capital.
Promoter Mona Anandbhai Desai created and released pledges on shares securing ₹578 Crore subsidiary debt. Net 14,60,625 shares (1.28%) remain encumbered post-transactions.
Anupam Rasayan India Ltd promoters Anand Sureshbhai Desai and Shraddha Anand Desai pledged 1,20,41,160 equity shares. The pledge serves as security for debt obligations and loans.
Anupam Rasayan corrected its previous disclosure regarding the acquisition of Bliss GVS Pharma Limited, clarifying the share counts acquired by the company and its PAC.
Anupam Rasayan India Ltd held its 23rd Annual General Meeting on September 30, 2026, through video conferencing to approve financial and operational matters.
Catalyst Trusteeship Limited received a pledge of 1,03,61,785 equity shares of Anupam Rasayan India Limited. This represents a 9.10% stake held as security for debenture holders.
Anupam Rasayan's subsidiary, Mates Visa Consultancy, will acquire a 47.95% stake in Bliss GVS Pharma Limited for ₹1,524.44 Crore to strengthen its pharmaceutical value chain.
Anupam Rasayan India Ltd acquired 22,50,000 shares of Bliss GVS Pharma Limited for ₹162.74 Crore, gaining control and being designated as its promoter.
Anupam Rasayan has completed the acquisition of a 48.2% controlling stake in Bliss GVS Pharma. The transaction was funded through Rs.1,750 Crore in capital.
Anupam Rasayan India Limited has allotted non-convertible debt securities. The company filed this disclosure in accordance with SEBI LODR requirements.
Anupam Rasayan India Ltd allotted 14,500 non-convertible debentures aggregating ₹145 Crore on a private placement basis. The proceeds will be used for debt repayment and corporate purposes.
Anupam Rasayan India Ltd. approved the private placement issuance of 16,000 non-convertible debentures (NCDs) aggregating to ₹160 Crore to Aditya Birla Capital Limited.
Anupam Rasayan approved a corporate guarantee of up to ₹300 Crore and a share pledge for financing availed by its subsidiary, Mates Visa Consultancy.
Anupam Rasayan India Ltd has scheduled a board meeting for September 19, 2026, to discuss potential fund-raising via a debt issue.
Anupam Rasayan India Ltd announced a Board Meeting on September 19, 2026, to consider raising up to ₹160 Crore via non-convertible debentures.